Adebrelimab + Apatinib in SCLC Maintenance Therapy
NCT06475209
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
SCLC
Interventions
DRUG:
Adebrelimab combined with Apatinib
Sponsor
Tang-Du Hospital
Collaborators
[object Object]